Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 11, 2023
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis
A Pinter, A Reich, P Arenberger, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
October 19, 2014
[Pancreatic panniculitis with multiple osteolytic lesions]
M Arenbergerova, P Alexandrova, S Gkalpakiotis, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 15, 2015
Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma
M Arenbergerova, A Fialova, S Gkalpakiotis, et al.
Ceska Gynekologie
|
September 18, 2013
[Vulvar melanoma]
M Arenbergerová, A Fialová, E Pojezná, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 30, 2017
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study
S Gerdes, D Thaçi, C E M Griffiths, et al.
The British Journal of Dermatology
|
October 28, 2018
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
K Reich, J Sullivan, P Arenberger, et al.
The British Journal of Dermatology
|
June 2, 2020
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
K Reich, J Sullivan, P Arenberger, et al.
The British Journal of Dermatology
|
October 28, 2016
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
C E M Griffiths, D Thaçi, S Gerdes, et al.
The British Journal of Dermatology
|
April 10, 2010
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study
D Thaçi, J-P Ortonne, S Chimenti, et al.
Journal of the American Academy of Dermatology
|
April 29, 1998
Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial
P Mayser, U Mrowietz, P Arenberger, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 11, 2023
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis
A Pinter, A Reich, P Arenberger, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
October 19, 2014
[Pancreatic panniculitis with multiple osteolytic lesions]
M Arenbergerova, P Alexandrova, S Gkalpakiotis, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 15, 2015
Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma
M Arenbergerova, A Fialova, S Gkalpakiotis, et al.
Ceska Gynekologie
|
September 18, 2013
[Vulvar melanoma]
M Arenbergerová, A Fialová, E Pojezná, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 30, 2017
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study
S Gerdes, D Thaçi, C E M Griffiths, et al.
The British Journal of Dermatology
|
October 28, 2018
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
K Reich, J Sullivan, P Arenberger, et al.
The British Journal of Dermatology
|
June 2, 2020
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
K Reich, J Sullivan, P Arenberger, et al.
The British Journal of Dermatology
|
October 28, 2016
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
C E M Griffiths, D Thaçi, S Gerdes, et al.
The British Journal of Dermatology
|
April 10, 2010
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study
D Thaçi, J-P Ortonne, S Chimenti, et al.
Journal of the American Academy of Dermatology
|
April 29, 1998
Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial
P Mayser, U Mrowietz, P Arenberger, et al.
Page
of 9